CSF β-amyloid predicts prognosis in patients with multiple sclerosis

Anna M. Pietroboni, Michela Caprioli, Tiziana Carandini, Marta Scarioni, Laura Ghezzi, Andrea Arighi, Sara Cioffi, Claudia Cinnante, Chiara Fenoglio, Emanuela Oldoni, Milena A. De Riz, Paola Basilico, Giorgio G. Fumagalli, Annalisa Colombi, Giovanni Giulietti, Laura Serra, Fabio Triulzi, Marco Bozzali, Elio Scarpini, Daniela Galimberti

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: The importance of predicting disease progression in multiple sclerosis (MS) has increasingly been recognized, and hence reliable biomarkers are needed. Objectives: To investigate the prognostic role of cerebrospinal fluid (CSF) amyloid beta1–42 (Aβ) levels by the determination of a cut-off value to classify patients in slow and fast progressors. To evaluate possible association with white matter (WM) and grey matter (GM) damage at early disease stages. Methods: Sixty patients were recruited and followed up for 3–5 years. Patients underwent clinical assessment, brain magnetic resonance imaging (MRI; at baseline and after 1 year), and CSF analysis to determine Aβ levels. T1-weighted volumes were calculated. T2-weighted scans were used to quantify WM lesion loads. Results: Lower CSF Aβ levels were observed in patients with a worse follow-up Expanded Disability Status Scale (EDSS; r = −0.65, p < 0.001). The multiple regression analysis confirmed CSF Aβ concentration as a predictor of patients’ EDSS increase (r = −0.59, p < 0.0001). Generating a receiver operating characteristic curve, a cut-off value of 813 pg/mL was determined as the threshold able to identify patients with worse prognosis (95% confidence interval (CI): 0.690–0.933, p = 0.0001). No differences in CSF tau and neurofilament light chain (NfL) levels were observed (p > 0.05). Conclusion: Low CSF Aβ levels may represent a predictive biomarker of disease progression in MS.

Original languageEnglish
JournalMultiple Sclerosis Journal
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Amyloid
Multiple Sclerosis
Cerebrospinal Fluid
Disease Progression
Biomarkers
Magnetic Resonance Imaging
Brain
White Matter

Keywords

  • Biomarkers
  • MRI
  • multiple sclerosis

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

CSF β-amyloid predicts prognosis in patients with multiple sclerosis. / Pietroboni, Anna M.; Caprioli, Michela; Carandini, Tiziana; Scarioni, Marta; Ghezzi, Laura; Arighi, Andrea; Cioffi, Sara; Cinnante, Claudia; Fenoglio, Chiara; Oldoni, Emanuela; De Riz, Milena A.; Basilico, Paola; Fumagalli, Giorgio G.; Colombi, Annalisa; Giulietti, Giovanni; Serra, Laura; Triulzi, Fabio; Bozzali, Marco; Scarpini, Elio; Galimberti, Daniela.

In: Multiple Sclerosis Journal, 01.01.2018.

Research output: Contribution to journalArticle

@article{21fd8cbf7ce945f1a8212659ad6dce61,
title = "CSF β-amyloid predicts prognosis in patients with multiple sclerosis",
abstract = "Background: The importance of predicting disease progression in multiple sclerosis (MS) has increasingly been recognized, and hence reliable biomarkers are needed. Objectives: To investigate the prognostic role of cerebrospinal fluid (CSF) amyloid beta1–42 (Aβ) levels by the determination of a cut-off value to classify patients in slow and fast progressors. To evaluate possible association with white matter (WM) and grey matter (GM) damage at early disease stages. Methods: Sixty patients were recruited and followed up for 3–5 years. Patients underwent clinical assessment, brain magnetic resonance imaging (MRI; at baseline and after 1 year), and CSF analysis to determine Aβ levels. T1-weighted volumes were calculated. T2-weighted scans were used to quantify WM lesion loads. Results: Lower CSF Aβ levels were observed in patients with a worse follow-up Expanded Disability Status Scale (EDSS; r = −0.65, p < 0.001). The multiple regression analysis confirmed CSF Aβ concentration as a predictor of patients’ EDSS increase (r = −0.59, p < 0.0001). Generating a receiver operating characteristic curve, a cut-off value of 813 pg/mL was determined as the threshold able to identify patients with worse prognosis (95{\%} confidence interval (CI): 0.690–0.933, p = 0.0001). No differences in CSF tau and neurofilament light chain (NfL) levels were observed (p > 0.05). Conclusion: Low CSF Aβ levels may represent a predictive biomarker of disease progression in MS.",
keywords = "Biomarkers, MRI, multiple sclerosis",
author = "Pietroboni, {Anna M.} and Michela Caprioli and Tiziana Carandini and Marta Scarioni and Laura Ghezzi and Andrea Arighi and Sara Cioffi and Claudia Cinnante and Chiara Fenoglio and Emanuela Oldoni and {De Riz}, {Milena A.} and Paola Basilico and Fumagalli, {Giorgio G.} and Annalisa Colombi and Giovanni Giulietti and Laura Serra and Fabio Triulzi and Marco Bozzali and Elio Scarpini and Daniela Galimberti",
year = "2018",
month = "1",
day = "1",
doi = "10.1177/1352458518791709",
language = "English",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",

}

TY - JOUR

T1 - CSF β-amyloid predicts prognosis in patients with multiple sclerosis

AU - Pietroboni, Anna M.

AU - Caprioli, Michela

AU - Carandini, Tiziana

AU - Scarioni, Marta

AU - Ghezzi, Laura

AU - Arighi, Andrea

AU - Cioffi, Sara

AU - Cinnante, Claudia

AU - Fenoglio, Chiara

AU - Oldoni, Emanuela

AU - De Riz, Milena A.

AU - Basilico, Paola

AU - Fumagalli, Giorgio G.

AU - Colombi, Annalisa

AU - Giulietti, Giovanni

AU - Serra, Laura

AU - Triulzi, Fabio

AU - Bozzali, Marco

AU - Scarpini, Elio

AU - Galimberti, Daniela

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: The importance of predicting disease progression in multiple sclerosis (MS) has increasingly been recognized, and hence reliable biomarkers are needed. Objectives: To investigate the prognostic role of cerebrospinal fluid (CSF) amyloid beta1–42 (Aβ) levels by the determination of a cut-off value to classify patients in slow and fast progressors. To evaluate possible association with white matter (WM) and grey matter (GM) damage at early disease stages. Methods: Sixty patients were recruited and followed up for 3–5 years. Patients underwent clinical assessment, brain magnetic resonance imaging (MRI; at baseline and after 1 year), and CSF analysis to determine Aβ levels. T1-weighted volumes were calculated. T2-weighted scans were used to quantify WM lesion loads. Results: Lower CSF Aβ levels were observed in patients with a worse follow-up Expanded Disability Status Scale (EDSS; r = −0.65, p < 0.001). The multiple regression analysis confirmed CSF Aβ concentration as a predictor of patients’ EDSS increase (r = −0.59, p < 0.0001). Generating a receiver operating characteristic curve, a cut-off value of 813 pg/mL was determined as the threshold able to identify patients with worse prognosis (95% confidence interval (CI): 0.690–0.933, p = 0.0001). No differences in CSF tau and neurofilament light chain (NfL) levels were observed (p > 0.05). Conclusion: Low CSF Aβ levels may represent a predictive biomarker of disease progression in MS.

AB - Background: The importance of predicting disease progression in multiple sclerosis (MS) has increasingly been recognized, and hence reliable biomarkers are needed. Objectives: To investigate the prognostic role of cerebrospinal fluid (CSF) amyloid beta1–42 (Aβ) levels by the determination of a cut-off value to classify patients in slow and fast progressors. To evaluate possible association with white matter (WM) and grey matter (GM) damage at early disease stages. Methods: Sixty patients were recruited and followed up for 3–5 years. Patients underwent clinical assessment, brain magnetic resonance imaging (MRI; at baseline and after 1 year), and CSF analysis to determine Aβ levels. T1-weighted volumes were calculated. T2-weighted scans were used to quantify WM lesion loads. Results: Lower CSF Aβ levels were observed in patients with a worse follow-up Expanded Disability Status Scale (EDSS; r = −0.65, p < 0.001). The multiple regression analysis confirmed CSF Aβ concentration as a predictor of patients’ EDSS increase (r = −0.59, p < 0.0001). Generating a receiver operating characteristic curve, a cut-off value of 813 pg/mL was determined as the threshold able to identify patients with worse prognosis (95% confidence interval (CI): 0.690–0.933, p = 0.0001). No differences in CSF tau and neurofilament light chain (NfL) levels were observed (p > 0.05). Conclusion: Low CSF Aβ levels may represent a predictive biomarker of disease progression in MS.

KW - Biomarkers

KW - MRI

KW - multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=85052502871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052502871&partnerID=8YFLogxK

U2 - 10.1177/1352458518791709

DO - 10.1177/1352458518791709

M3 - Article

AN - SCOPUS:85052502871

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

ER -